Document is current
Any future updates will be listed below
-
Authors
Yalikun, Kugeluke
Li, Zhongchao
Zhang, Jianxin
Chang, Zhibin
Li, Mingming
Sun, Zhicheng
Liu, Zhaogang
Yang, Yue
Xu, Lei
Li, Lei
Zhang, Chengsheng
Sun, Pengfei
Zhong, Jingtao
Cui, Kai
Shi, Xuetao
Zhang, Bo
Zhao, Lei
-
Funding
Funding for this research was provided by:
Wu Jieping Medical Foundation (320 .6750.2022-09-19)
National Natural Science Fund of China (81872400)
The Key Research and Development Program of Shandong (2021SFGC0501)
Joint Innovation and Development Item of Shandong Natural Scientific Fund (ZR2021LZL008)
- License Information
-
More Information
Article History
Received: 25 October 2024
Accepted: 29 April 2025
First Online: 7 May 2025
Declarations
:
: All patients provided written informed consent, and the Shandong Cancer Hospital Research Institute Ethics Committee approved the protocol (No. SDZLEC2021-021–01).
: Not applicable.
: L.Z. is on the speakers’ bureau for Bayer, MSD, AstraZeneca, Roche, BeiGene, Innovent, Junshi Biosciences and Jiangsu Hengrui Pharmaceuticals. The remaining authors declare no competing interests.
